证券代码：300765 证券简称：新诺威 公告编号：2025-046 石药创新制药股份有限公司 关于控股股东增持公司股份计划实施完成的公告 控股股东石药集团恩必普药业有限公司保证向本公司提供的信息内容真 实、准确、完整，没有虚假记载、误导性陈述或重大遗漏。 特别提示： 本公司及董事会全体成员保证公告内容与信息披露义务人提供的信息一 致。 1、石药创新制药股份有限公司（以下简称"公司"）于 2024 年 11 月 8 日 披露《关于控股股东增持公司股份计划的公告》（公告编号：2024-102），公司 控股股东石药集团恩必普药业有限公司（以下简称"恩必普药业"）计划自 2024 年 11 月 8 日（含本日）起 6 个月内，择机增持公司股份，增持金额不低于人民 币 10,000.00 万元，不超过人民币 12,000.00 万元。 2、增持计划的进展情况：截至本公告披露日，恩必普药业的增持计划已实 施完成。自 2024 年 11 月 8 日至 2025 年 5 月 7 日，恩必普药业通过深圳证券交 易所交易系统以集中竞价方式累计增持公司股份 3,313,900 股，占公司总股本的 0.24%（已剔除最新披露的公司 ...

关于 石药创新制药股份有限公司 控股股东增持公司股份 之 法律意见书 中国北京东城区金宝街 89 号金宝大厦 11 层 邮编：100005 11F, Jinbao Tower, 89 Jinbao Street, Dongcheng District, Beijing 100005, P.R.C. 电话(Tel)： (86-10) 6652 3388 传真(Fax)：（86-10）6652 3399 网址（Website）： www.junzejun.com 电子信箱（E-mail）：jzj@junzejun.com 释 义 在本法律意见书中，除非文义另有所指，下列左栏中的术语或简称对应右栏 中的含义或全称： | 公司、新诺威 | 指 | 石药创新制药股份有限公司 | | --- | --- | --- | | 增持人、控股股东、恩必 | 指 | 石药集团恩必普药业有限公司，现为公司控股股东 | | 普药业 | | | | 本次增持 | 指 | 恩必普药业拟自 2024 年 11 月 8 日（含本日）起 6 个月内， 万元， | | | | 择机增持公司股份，增持金额不低于人民币 10,000.00 | | ...

Core Viewpoint - New Nuo Wei (300765.SZ) announced the termination of its application for the acquisition of Shiyao Chuangxin Pharmaceutical Co., Ltd. and the associated fundraising, ending a 15-month effort for a significant restructuring deal worth 7.6 billion yuan [2][3]. Group 1: Termination of Acquisition - The termination was due to changes in the pharmaceutical industry and capital market environment since the initial planning of the restructuring, leading to a decision made in the interest of long-term shareholder benefits [2][3]. - The market reacted rationally to the termination, influenced by factors such as stock price fluctuations, increasing performance burdens, and declining acquisition targets [2][3]. Group 2: Financial Performance and Challenges - New Nuo Wei's revenue and profit have been declining, with a 21.98% year-on-year decrease in revenue to 1.981 billion yuan and an 87.63% drop in net profit to 54 million yuan in 2024 [8]. - The company's core revenue from functional foods and raw materials fell by 24.90% to 1.84 billion yuan, while the biopharmaceutical sector contributed only 87.8 million yuan, despite a 153.0% increase [10]. Group 3: Acquisition Details and Valuation - The acquisition target, Shiyao Baike, has a core product, Jinyouli, which is facing growth challenges, with a significant reliance on a single product and limited growth potential [4][7]. - The valuation for Shiyao Baike was set at 7.622 billion yuan, representing a 78.25% premium over its book value of 4.276 billion yuan, raising concerns about the high price for low-growth assets [6][7]. Group 4: R&D and Future Prospects - New Nuo Wei's R&D expenses increased by 25.44% to 842 million yuan in 2024, primarily due to the inclusion of Shiji Biological's R&D costs, indicating a significant financial burden [10][11]. - The company is under pressure from negative cash flows, with net cash flow from operating activities at -1.235 billion yuan in 2024 and -87 million yuan in the first quarter of 2025 [12][13].

Core Viewpoint - New Nuo Wei (300765.SZ) has terminated its acquisition of Shiyao Baike, with the Shenzhen Stock Exchange halting the review of the asset purchase and fundraising application due to changes in the pharmaceutical industry and capital market conditions since the initial planning of the restructuring [1][3]. Group 1: Acquisition Details - The acquisition was initially approved by New Nuo Wei's board in January 2024, intending to purchase 100% of Shiyao Baike for a total consideration of 7.6 billion yuan, with 90% paid in shares and 10% in cash [2][3]. - The transaction was expected to enhance New Nuo Wei's biopharmaceutical portfolio, particularly in long-acting proteins and innovative drug pipelines [2][3]. Group 2: Financial Performance - New Nuo Wei has experienced a decline in revenue and net profit for two consecutive years, with revenues of 25.39 billion yuan in 2023 and 19.81 billion yuan in 2024, representing year-on-year decreases of 4.75% and 21.98%, respectively [6]. - The net profit for 2023 and 2024 was reported at 4.34 billion yuan and 537.26 million yuan, showing declines of 40.18% and 87.63% year-on-year [6]. - In Q1 2025, New Nuo Wei reported revenues of 472 million yuan, a 9.94% decrease year-on-year, and a net loss of 26.90 million yuan compared to a profit of 79.06 million yuan in the same period the previous year [8]. Group 3: R&D and Market Conditions - The company has significantly increased its R&D expenditures, reaching 840 million yuan in 2024, a 25.44% increase from the previous year, with Q1 2025 R&D expenses at 240 million yuan, up 117.68% year-on-year [6][9]. - New Nuo Wei's strategic focus includes ADCs, mRNA vaccines, and antibody drugs, with over 20 products in the pipeline and several achieving important milestones in 2024 [7].

Core Insights - The latest net value of ICBC Frontier Medical Stock A (001717) is 2.8300 yuan, reflecting a decrease of 1.77% [1] - The fund has shown a one-month return of 5.28%, ranking 400 out of 471 in its category; a three-month return of 8.06%, ranking 71 out of 471; and a year-to-date return of 7.56%, ranking 113 out of 469 [1] Fund Holdings - The top ten holdings of ICBC Frontier Medical Stock A account for a total of 59.05%, with the largest positions being: - Heng Rui Medicine (10.11%) - Kelun Pharmaceutical (8.01%) - WuXi AppTec (7.72%) - BeiGene (6.85%) - Xinlitai (4.90%) - Zai Lab (4.77%) - Yuyue Medical (4.60%) - New Horizon Health (4.36%) - East China Pharmaceutical (4.20%) - Haizhi Pharmaceutical (3.53%) [1] Fund Overview - ICBC Frontier Medical Stock A was established on February 3, 2016, and as of March 31, 2025, it has a total scale of 9.081 billion yuan [1] - The fund manager is Zhao Bei, who has extensive experience in the healthcare sector [2]

Group 1: Termination of Asset Restructuring - The termination of the asset restructuring will not have a significant adverse impact on the company's existing operations and strategic planning [1][2][4] - The decision to terminate the restructuring was made after careful consideration of the pharmaceutical industry and capital market conditions [2][4] - The company will not plan any major asset restructuring for at least one month following the announcement of the termination [2][4] Group 2: Business Operations and Future Plans - The company will continue to focus on research and development, enhancing drug development efficiency [2][3][4] - Ongoing projects, including the construction of production lines for monoclonal antibodies and ADC new products, are progressing normally [3][4] - As of April 30, 2025, the number of shareholders was 12,217 [2][5] Group 3: Innovation and Market Strategy - The company aims to establish a comprehensive research pipeline by continuously exploring new molecules and maintaining a high-efficiency research progress [2][3] - Future product lines will focus on cutting-edge areas such as ADC, mRNA vaccines, and antibody drugs [2][5] - The company is committed to creating greater value for investors through sustained innovation and improved management [2][4]

新诺威（300765）公告，公司于2025年4月30日收到深交所出具的《关于终止对石药创新制药股份有限 公司发行股份购买资产并募集配套资金申请审核的决定》，因公司及独立财务顾问国投证券股份有限公 司、中信证券股份有限公司提交了撤回发行股份购买资产并募集配套资金暨关联交易申请的文件，根据 《深圳证券交易所上市公司重大资产重组审核规则(2024年修订)》第五十二条的有关规定，深交所决定 终止对公司发行股份购买资产并募集配套资金申请的审核。 ...

证券代码：300765 证券简称：新诺威 公告编号：2025-045 石药创新制药股份有限公司 关于收到深圳证券交易所《关于终止对石药创新制药股份有 限公司发行股份购买资产并募集配套资金申请审核的决定》 的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 石药创新制药股份有限公司（以下简称"公司"）于 2025 年 4 月 28 日召开 第六届董事会第二十四次会议、第六届监事会第十九次会议，审议通过了《关于 终止发行股份及支付现金购买资产并募集配套资金暨关联交易事项并撤回申请 文件的议案》，同意公司终止发行股份及支付现金购买资产并募集配套资金暨关 联交易事项并撤回申请文件 。具体内容详见公司同日在巨潮资讯网 （http://www.cninfo.com.cn）披露的《关于终止发行股份及支付现金购买资产并 募集配套资金暨关联交易事项并撤回申请文件的公告》（公告编号：2025-042）。 公司于 2025 年 4 月 29 日向深圳证券交易所（以下简称"深交所"）提交了 《石药创新制药股份有限公司关于撤回发行股份购买资产并募集配套资金申请 文件的申请》，向深交 ...

Group 1 - The core viewpoint of the news is the performance and holdings of the Industrial and Commercial Bank of China Medical Healthcare Stock Fund, which has shown positive growth in recent months and has a diversified portfolio in the healthcare sector [1][3]. - As of April 30, 2025, the latest net value of the fund is 2.5180 yuan, reflecting a growth of 1.82%. The fund's return over the past month is 2.07%, ranking 41 out of 469 in its category. Over the past three months, the return is 11.71%, ranking 45 out of 467, and since the beginning of the year, the return is 10.49%, ranking 44 out of 465 [1]. - The fund's total assets amount to 2.724 billion yuan as of March 31, 2025, and it was established on November 18, 2014. The fund managers are Zhao Bei and Ding Yang [1]. Group 2 - The top ten holdings of the fund account for a total of 39.79%, with significant investments in companies such as Heng Rui Pharmaceutical (8.90%), WuXi AppTec (5.12%), and Aier Eye Hospital (4.94%) [1]. - Zhao Bei, the fund manager, has extensive experience in the healthcare sector, having been with ICBC Credit Suisse Asset Management since 2010 and managing the healthcare fund since its inception in 2014. Ding Yang, the co-manager, has a strong academic background and joined the firm in 2017 [2].

证券代码：300765 证券简称：新诺威 公告编号：2025-044 石药创新制药股份有限公司 关于使用部分闲置募集资金进行现金管理的进展公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 石药创新制药股份有限公司（以下简称"公司"）于 2025 年 3 月 19 日召开第 六届董事会第二十二次会议、第六届监事会第十七次会议，于 2025 年 4 月 15 日 召开 2024 年年度股东大会，会议审议并通过了《关于使用部分闲置募集资金及 自有资金进行现金管理的议案》。在不影响募集资金投资项目建设和公司正常经 营的情况下，公司及子公司使用不超过人民币 8.00 亿元（含本数）额度的闲置募 集资金及不超过人民币 8.00 亿元（含本数）的自有资金进行现金管理，投资安全 性高、流动性好的保本型产品（包括结构性存款、大额存单等），使用期限自股 东大会审议通过之日起 12 个月内有效。在上述额度及决议有效期内，业务可循 环滚动开展。具体内容详见巨潮资讯网（http://www.cninfo.com.cn）披露的《关 于使用部分闲置募集资金及自有资金进行现金管理的公告》 ...